SEARCH

SEARCH BY CITATION

Figure S1: HCMV-specific IFNG responses in representative HCMV-seropositive patients. (A, B) Representative HCMV-seropositive patients who displayed high-level HCMV DNAemia (plasma HCMV DNA loads exceeding 1000 copies/mL) and undetectable HCMV-specific IFNG responses during the entire follow-up (A) or detectable and stable responses (B). (C, D) Representative HCMV-seropositive patients with low-level HCMV DNAemia (plasma HCMV DNA loads equal to or lower than 1000 copies/mL) who showed HCMV-specific IFNG responses that were detected early during (C) or after antiviral prophylaxis (D) and remained stable thereafter.

Figure S2: HCMV-specific IFNG responses in representative HCMV-seronegative patients and in a seropositive patient with HCMV disease. (A, B, C) Representative HCMV-seronegative patients who developed primary HCMV-specific IFNG responses after high-level HCMV DNAemia (plasma HCMV DNA loads exceeding 1000 copies/mL) (A), low-level HCMV DNAemia (plasma HCMV DNA loads equal to or lower than 1000 copies/mL) (B) and no detectable HCMV DNAemia during the entire follow-up (C). (D) Representative patient with a D+/R+ constellation who showed fluctuations of HCMV-specific IFNG responses that decreased before high level HCMV DNAemia and HCMV disease.

FilenameFormatSizeDescription
AJT_4076_sm_Figure_S1.ppt83KSupporting info item
AJT_4076_sm_Figure_S2.ppt86KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.